spacer
home > ebr > spring 2018 > precision healthcare
PUBLICATIONS
European Biopharmaceutical Review

Precision Healthcare

At the end of January, industry observers were brimming with speculation on the likely course of Amazon’s entry into healthcare. Championed by a corporation known for ‘disruptive innovation’ in the technology and retail sectors, this project promises to challenge the status quo in the world’s largest healthcare system that is characterised by a fragmented market, entrenched providers, dysfunctional incentives, and little consumer choice.

The manifesto of this bold project by Amazon, JP Morgan, and Berkshire- Hathaway is both challenging and modest: “Our goal is to benefit [1.2 million] US employees and their families, and potentially all Americans.” In short, the goal is to remake the market for healthcare so it becomes integrated, transparent, equitable, and more affordable. Success would not be measured by immediate financial returns, but by long-term impact. Many analysts saw the venture as the opening gambit in online retail pharmacy. This has been the buzz since Amazon acquired Whole Foods Markets last year. Consumers will derive benefit from the online utility of Amazon, as Alibaba is already proving in China.

Amazon fields best-in-class e-commerce, distribution, fulfilment, and technology. In the industry press, the mantra was ‘bricks and clicks’, but in classic economic theory, such an enterprise could upend the supply chain by disintermediation, while using its purchasing power to lower costs to consumers and achieving dominance by sheer scale and reach. Consumer costs would certainly decrease by leveraging the existing customer base and Amazon skill sets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a China watcher, and an industry consultant with experience in the biotechnology and biopharmaceutical industries.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cambridge Sensotec (manufacturers of Dynascan) obtains new ISO accreditation

On the 30th May 2019, Cambridge Sensotec proudly achieved ISO 9001:2015 accreditation under the BSI (British Standards Institution). Cambridge Sensotec Ltd now joins 1.3 million companies across 112 countries worldwide that hold this prestigious certificate.
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement